ArticleJournal of arrhythmia2025
A cross-tissue transcriptome-wide association study identifies novel susceptibility genes for atrial fibrillation.
Article in Journal of arrhythmia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genomic Structural Equation Modeling Combined With Post-GWAS Analysis Identifies Two Risk Gene Loci and Functionally Sensitive Genes Associated With Cardiac Conduction Block.Genetics research · 2026Article
- A cross-tissue transcriptome-wide association study identifies novel susceptibility genes for atrial fibrillation.Journal of arrhythmia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF), the most common cardiac arrhythmia, has been linked to numerous loci identified by genome-wide association studies (GWAS). However, the causal genes and underlying mechanisms remain unclear. Methods: We conducted a cross-tissue transcriptome-wide association studies (TWAS) using the unified test for molecular signatures (UTMOST), integrating genetic data from the FinnGen R11 cohort (287 805 individuals) with gene expression profiles from the genotype-tissue expression (GTEx) project. To enhance reliability, we applied functional summary-based imputation (FUSION), fine-mapping of causal gene sets (FOCUS), and multi-marker analysis of GenoMic annotation (MAGMA) for gene prioritization, followed by Mendelian randomization (MR) and colocalization analyses. GeneMANIA was used to explore gene functions. Results: By integrating four TWAS approaches, this study identified five novel susceptibility genes significantly associated with AF risk. MR analysis further revealed that the gene expression levels of FKBP7, CEP68, and CAMK2D were positively associated with AF risk, while SPATS2L exhibited a significant protective effect. Colocalization analysis demonstrated that CEP68 and SPATS2L share causal variants with AF. Through comprehensive evaluation of multidimensional functional annotations and existing biological evidence, this study highlighted SPATS2L and CEP68 as potential functional candidate genes in AF pathogenesis. Conclusions: This cross-tissue TWAS identified five novel AF susceptibility genes (CAMK2D, SPAST2L, CEP68, FKBP7, and SHRMOO3). Elevated expression of FKBP7, CEP68, and CAMK2D increases AF risk, while SPATS2L showed a protective effect, with colocalization analysis implicating CEP68 and SPATS2L as prioritized candidates. The integration of multi-omics approaches effectively unravels AF's genetic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.